MorphoSys AG / MorphoSys to Present Data on Proprietary Programs at American Society of Hematology Annual Meeting . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
List of All Abstracts:
A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma:
http://bit.ly/1y8GpNm
Final Results and Follow-up of a Phase I Study of the Fc Engineered CD19 Antibody XmAb®5574 (aka MOR00208) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL):
http://bit.ly/1y8GSiv
www.hematology.org/Meetings/Annual-Meeting and http://bloodjournal.hematologylibrary.org/:
http://www.hematology.org/Meetings/Annual-Meeting
http://www.bloodjournal.org/content/early/2014/10/09/blood-2014-08-593269 :
http://www.bloodjournal.org/content/early/2014/10/09/blood-2014-08-593269
About MorphoSys:
pipeline :
http://www.morphosys.com/pipeline
For more information, please contact:
http://hugin.info/130295/R/1869280/657224.pdf
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / Munich Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;